bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen

Cowen analyst Eric Schmidt reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE) noting a late-breaker ASH abstract provides proof-of-concept for anti-BCMA CAR.

Schmidt commented, "A late breaking ASH abstract reports on the first data from an anti-BCMA CAR in myeloma. Although partners BLUE/CELG will test a new and hopefully improved construct in early 2016, this NCI-run trial provides clear evidence of activity in highly refractory patients and increases our optimism in the strategy's likely success. We expect this program to support increased interest in BLUE shares."

LINK to abstract

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $71.39 yesterday.

You May Also Be Interested In

• The Lovesac Co. (LOVE) PT Raised to $20 at DA Davidson Following Q1 Results
• Adobe (ADBE) PT Lowered to $285 at RBC Capital
• BMO Capital on PrairieSky Royalty Ltd (PSK:CN) (PREKF): 'The Growth Is Coming'